[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE0201778D0 - Process for the manufacture of quinoline derivatives - Google Patents

Process for the manufacture of quinoline derivatives

Info

Publication number
SE0201778D0
SE0201778D0 SE0201778A SE0201778A SE0201778D0 SE 0201778 D0 SE0201778 D0 SE 0201778D0 SE 0201778 A SE0201778 A SE 0201778A SE 0201778 A SE0201778 A SE 0201778A SE 0201778 D0 SE0201778 D0 SE 0201778D0
Authority
SE
Sweden
Prior art keywords
manufacture
quinoline derivatives
formula
quinoline
chaineded
Prior art date
Application number
SE0201778A
Other languages
English (en)
Inventor
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0201778A priority Critical patent/SE0201778D0/sv
Publication of SE0201778D0 publication Critical patent/SE0201778D0/sv
Priority to KR1020047020088A priority patent/KR100979216B1/ko
Priority to JP2004513257A priority patent/JP4584709B2/ja
Priority to CNB038135310A priority patent/CN100418950C/zh
Priority to UA20041109639A priority patent/UA78310C2/xx
Priority to MXPA04012276A priority patent/MXPA04012276A/es
Priority to MEP-2008-656A priority patent/ME00435B/me
Priority to HRP20050028AA priority patent/HRP20050028B1/hr
Priority to BRPI0311674-3A priority patent/BR0311674A/pt
Priority to ES03725956T priority patent/ES2278160T3/es
Priority to AU2003228195A priority patent/AU2003228195B2/en
Priority to SI200330688T priority patent/SI1511732T1/sl
Priority to YUP-1076/04A priority patent/RS51021B/sr
Priority to RU2005100054/04A priority patent/RU2291861C2/ru
Priority to PCT/SE2003/000780 priority patent/WO2003106424A1/en
Priority to DE60310554T priority patent/DE60310554T2/de
Priority to EP03725956A priority patent/EP1511732B9/en
Priority to PL373817A priority patent/PL210259B1/pl
Priority to AT03725956T priority patent/ATE348814T1/de
Priority to CA2487329A priority patent/CA2487329C/en
Priority to DK03725956T priority patent/DK1511732T5/da
Priority to PT03725956T priority patent/PT1511732E/pt
Priority to NZ536768A priority patent/NZ536768A/en
Priority to IL165155A priority patent/IL165155A/en
Priority to ZA200409430A priority patent/ZA200409430B/xx
Priority to IS7550A priority patent/IS2975B/is
Priority to NO20045703A priority patent/NO329162B1/no
Priority to CY20071100295T priority patent/CY1107555T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0201778A 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives SE0201778D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives
NZ536768A NZ536768A (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline carboxamide derivatives using an alkane or cycloalkane solvent
YUP-1076/04A RS51021B (sr) 2002-06-12 2003-05-14 Postupak za dobijanje derivata hinolina
PCT/SE2003/000780 WO2003106424A1 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
CNB038135310A CN100418950C (zh) 2002-06-12 2003-05-14 制备喹啉衍生物的方法
UA20041109639A UA78310C2 (en) 2002-06-12 2003-05-14 Method for preparing quinolin derivatives
MXPA04012276A MXPA04012276A (es) 2002-06-12 2003-05-14 Proceso para la elaboracion de derivados de quinolina.
MEP-2008-656A ME00435B (me) 2002-06-12 2003-05-14 Postupak za dobijanje derivata hinolina
HRP20050028AA HRP20050028B1 (hr) 2002-06-12 2003-05-14 Postupak za proizvodnju derivata kinolina
BRPI0311674-3A BR0311674A (pt) 2002-06-12 2003-05-14 processo para a preparação de compostos
ES03725956T ES2278160T3 (es) 2002-06-12 2003-05-14 Procedimiento para la fabricacion de derivados de quinolina.
AU2003228195A AU2003228195B2 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
SI200330688T SI1511732T1 (sl) 2002-06-12 2003-05-14 Postopek za pripravo kinolinskih derivatov
KR1020047020088A KR100979216B1 (ko) 2002-06-12 2003-05-14 퀴놀린 유도체의 제조 방법
RU2005100054/04A RU2291861C2 (ru) 2002-06-12 2003-05-14 Способ получения производных хинолина
JP2004513257A JP4584709B2 (ja) 2002-06-12 2003-05-14 キノリン誘導体の製造工程
DE60310554T DE60310554T2 (de) 2002-06-12 2003-05-14 Verfahren zur herstellung von chinolinderivaten
EP03725956A EP1511732B9 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
PL373817A PL210259B1 (pl) 2002-06-12 2003-05-14 Sposób wytwarzania pochodnych chinoliny
AT03725956T ATE348814T1 (de) 2002-06-12 2003-05-14 Verfahren zur herstellung von chinolinderivaten
CA2487329A CA2487329C (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
DK03725956T DK1511732T5 (da) 2002-06-12 2003-05-14 Fremgangsmåde til fremstilling af quinolinderivater
PT03725956T PT1511732E (pt) 2002-06-12 2003-05-14 Processo para o fabrico de derivados quinolina
IL165155A IL165155A (en) 2002-06-12 2004-11-11 A process to create a history of quinoline
ZA200409430A ZA200409430B (en) 2002-06-12 2004-11-23 Process for the manufacture of quinoline derivatives.
IS7550A IS2975B (is) 2002-06-12 2004-11-24 Aðferð til framleiðslu á kvínólín-afleiðum
NO20045703A NO329162B1 (no) 2002-06-12 2004-12-29 Fremgangsmate ved fremstilling av quinolin-derivater
CY20071100295T CY1107555T1 (el) 2002-06-12 2007-03-01 Μεθοδος για την βιομηχανικη παρασκευη παραγωγων κινολινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives

Publications (1)

Publication Number Publication Date
SE0201778D0 true SE0201778D0 (sv) 2002-06-12

Family

ID=20288148

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives

Country Status (28)

Country Link
EP (1) EP1511732B9 (sv)
JP (1) JP4584709B2 (sv)
KR (1) KR100979216B1 (sv)
CN (1) CN100418950C (sv)
AT (1) ATE348814T1 (sv)
AU (1) AU2003228195B2 (sv)
BR (1) BR0311674A (sv)
CA (1) CA2487329C (sv)
CY (1) CY1107555T1 (sv)
DE (1) DE60310554T2 (sv)
DK (1) DK1511732T5 (sv)
ES (1) ES2278160T3 (sv)
HR (1) HRP20050028B1 (sv)
IL (1) IL165155A (sv)
IS (1) IS2975B (sv)
ME (1) ME00435B (sv)
MX (1) MXPA04012276A (sv)
NO (1) NO329162B1 (sv)
NZ (1) NZ536768A (sv)
PL (1) PL210259B1 (sv)
PT (1) PT1511732E (sv)
RS (1) RS51021B (sv)
RU (1) RU2291861C2 (sv)
SE (1) SE0201778D0 (sv)
SI (1) SI1511732T1 (sv)
UA (1) UA78310C2 (sv)
WO (1) WO2003106424A1 (sv)
ZA (1) ZA200409430B (sv)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
EP1937642B1 (en) 2005-10-19 2014-09-10 Teva Pharmaceutical Industries Ltd Crystals of laquinimod sodium, and process for the manufacture thereof
NZ573846A (en) * 2006-06-12 2012-01-12 Teva Pharma Stable laquinimod preparations
EA200900749A1 (ru) 2006-11-28 2009-12-30 Валеант Фармасьютикалс Интернэшнл 1,4-диаминобициклические аналоги ретигабина как модуляторы калиевых каналов
EP2682120B1 (en) 2007-12-20 2016-08-03 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2010028015A2 (en) 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
SI2458992T1 (sl) 2009-07-30 2016-03-31 Teva Pharmaceutical Industries Ltd. Zdravljenje Crohnove bolezni z lakvinimodom
DK2467372T3 (en) 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
SG10201501535UA (en) 2010-03-03 2015-04-29 Teva Pharma Treatment of lupus nephritis using laquinimod
DK2542079T3 (da) 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
JP5881691B2 (ja) * 2010-07-09 2016-03-09 アクティブ バイオテック エイビー キノリン−３−カルボキサミドの製造方法
AU2011274502A1 (en) * 2010-07-09 2013-02-28 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
EP3225617A1 (en) 2012-02-16 2017-10-04 Teva Pharmaceutical Industries Ltd N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
KR20150091077A (ko) 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
HK1220444A1 (zh) * 2013-03-14 2017-05-05 Teva Pharmaceutical Industries Ltd. 拉喹莫德鈉晶體和用於製造它們的改進方法
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治療具有高殘疾狀況的復發-緩解型多發性硬化症(rrms)的患者的拉喹莫德
WO2016042112A1 (en) 2014-09-23 2016-03-24 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
EP3180005B1 (en) 2014-11-19 2017-12-27 Active Biotech AB Quinoline carboxamides for use in the treatment of leukemia
IL295780A (en) 2020-03-03 2022-10-01 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
WO2022018240A1 (en) 2020-07-23 2022-01-27 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
MX2023008016A (es) 2021-01-18 2023-07-13 Active Biotech Ab Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
EP4346773B1 (en) 2021-05-25 2025-07-02 Active Biotech AB A plurality of tasquinimod particles and use thereof
KR20240029029A (ko) 2021-07-02 2024-03-05 액티브 바이오테크 에이비 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
BR0311674A (pt) 2008-01-08
NO20045703L (no) 2004-12-29
HRP20050028A2 (en) 2006-02-28
ZA200409430B (en) 2006-02-22
EP1511732A1 (en) 2005-03-09
IS7550A (is) 2004-11-24
IL165155A (en) 2009-11-18
PT1511732E (pt) 2007-03-30
SI1511732T1 (sl) 2007-06-30
CN1659146A (zh) 2005-08-24
HRP20050028B1 (hr) 2013-07-31
AU2003228195B2 (en) 2009-05-28
JP4584709B2 (ja) 2010-11-24
DK1511732T5 (da) 2007-10-01
CN100418950C (zh) 2008-09-17
DE60310554D1 (de) 2007-02-01
RU2291861C2 (ru) 2007-01-20
UA78310C2 (en) 2007-03-15
CY1107555T1 (el) 2013-03-13
ATE348814T1 (de) 2007-01-15
DE60310554T2 (de) 2007-11-29
RU2005100054A (ru) 2005-07-10
JP2005535612A (ja) 2005-11-24
NZ536768A (en) 2006-10-27
MXPA04012276A (es) 2005-04-08
EP1511732B9 (en) 2008-11-12
RS107604A (en) 2007-02-05
DK1511732T3 (da) 2007-04-30
NO329162B1 (no) 2010-08-30
EP1511732B1 (en) 2006-12-20
RS51021B (sr) 2010-10-31
PL373817A1 (en) 2005-09-19
PL210259B1 (pl) 2011-12-30
ME00435B (me) 2011-10-10
WO2003106424A1 (en) 2003-12-24
AU2003228195A1 (en) 2003-12-31
CA2487329C (en) 2010-11-16
IL165155A0 (en) 2005-12-18
CA2487329A1 (en) 2003-12-24
ES2278160T3 (es) 2007-08-01
KR100979216B1 (ko) 2010-08-31
KR20050016537A (ko) 2005-02-21
IS2975B (is) 2017-07-15

Similar Documents

Publication Publication Date Title
SE0201778D0 (sv) Process for the manufacture of quinoline derivatives
CY1106598T1 (el) Παραγωγα κινολινης και ισοκινολινης, μεθοδος για την παραγωγη αυτων και χρηση αυτων ως αντιφλεγμονωδη μεσα
RS50918B (sr) Novi estri fluorenkarbonske kiseline, postupak za njihovo pripremanje, kao i njihova upotreba kao lekova
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
NO20062644L (no) DPP-IV inhibitorer
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
DK1601653T3 (da) Fremgangsmåde til fremstilling af substituerede nikotinsyreestre
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
NO20032731L (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
NO20055099L (no) Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner
MY141020A (en) Novel pparalpha and ppargamma agonists
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
PE20010029A1 (es) Androgenos oralmente activos
NO20031046L (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
NO20055924L (no) Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater
ES2184633A1 (es) Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
TR200200307T2 (tr) Alfa-Kloroepoksi esterleri vasıtasıyla asit hazırlama prosesi
TW200621807A (en) Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound
ATE337348T1 (de) Beschichtungen aus speziellen polyolen und oxalsäure
NO20044045L (no) Ny fremgangsmate
TH72657A (th) สารประกอบ
DE602004018276D1 (de) Nitratester von phenylaminothiophen-essigsäurederivaten
NO20044627L (no) Polysykliske forbindelser som sterke alfa2-adrenoseptorantagonister